Shares of immuno-oncology company Marker Therapeutics (NASDAQ:MRKR) are soaring higher today after it announced pre-clinical data for its T cell product candidate MT-601 in lymphoma cells (including CD19 CAR T refractory cells).
MT-601 was evaluated in the Baylor TACTAL study with subjects with Hodgkin’s and non-Hodgkin’s lymphoma. Impressively, some subjects achieved complete remission (CR) and were still in remission at 72 months follow-up.
Recently, the company has begun evaluating MT-601’s safety and efficacy (recognition of six antigens versus the earlier five) and is exploring the potential benefits of the therapy in a multicentre Phase 1 clinical trial (initiated in Q1).
Additionally, the company is also reviewing clinical opportunities for MT601, and further updates on its clinical strategy and expected milestones are awaited.
With today’s price gains, MRKR shares have now zoomed nearly 58% over the past month.
Read full Disclosure
